In last week’s (free) Wednesday newsletter, we discussed Sorrento Therapeutics Inc. ($SRNE), a biopharma company that (supposedly) develops treatments for three major therapeutic areas: cancer, infectious disease and pain. It and an affiliate (together, the “debtors”) crashed into bankruptcy in the Southern District of Texas (Judge Jones) on February 13…